00_MJ_Intro_Budapest16.pptx

Previous Page

Next Page

Page Background

1/03/2016

9

Efficacy

Bonner Lancet Oncol 2010

3y OS rate: 55.0% vs 45.0% (p=0.05)

5y OS rate: 45.6% vs 36.4% (p<0.05)

•

Cetuximab+RT improves OS compared with RT

Adverse events

18

Bonner NEJM 2006